WASHINGTON (AP) — A new strategy to fight an extremely aggressive type of brain tumor showed promise in a pair of experiments with a handful of patients.
Scientists took patients’ own immune cells and turned them into “living drugs” able to recognize and attack glioblastoma. In the first-step tests, those cells shrank tumors at least temporarily, researchers reported Wednesday.
So-called CAR-T therapy already is used to fight blood-related cancers like leukemia but researchers have struggled to make it work for solid tumors. Now separate teams at Massachusetts General Hospital and the University of Pennsylvania are developing next-generation CAR-T versions designed to get past some of glioblastoma’s defenses.
“It’s very early days,” cautioned Penn’s Dr. Stephen Bagley, who led one of the studies. But “we’re optimistic that we’ve got something to build on here, a real foundation.”
Hundreds of hostages, mostly women and children, are rescued from Boko Haram extremists in Nigeria
Israel to open three humanitarian routes into Gaza
Yang Hengjun: Australian writer detained in China fears he will die in jail
Winston Peters to meet Anthony Blinken and Trump official in Washington
Iran's nuclear policy unlikely to change even after president's death
'Major logistics exercise' to deliver humanitarian aid from NZ to Gaza
Israeli military says troops captured hundreds of fighters in Gaza hospital
Four killed, several injured as race car hits spectators at Hungary rally
New Zealand Black Caps fans look to Twenty20 World Cup with hope, trepidation
China economy update: Evergrande shares plunge 70 per cent